145 related articles for article (PubMed ID: 38501262)
1. Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer - a plain language summary.
González-Martín A; Pothuri B; Vergote I; Graybill W; Lorusso D; McCormick CC; Freyer G; Backes F; Heitz F; Redondo A; Moore RG; Vulsteke C; O'Cearbhaill RE; Malinowska IA; Shtessel L; Compton N; Mirza MR; Monk BJ
Future Oncol; 2024 Mar; ():1-14. PubMed ID: 38501262
[TBL] [Abstract][Full Text] [Related]
2. Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial.
Barretina-Ginesta MP; Monk BJ; Han S; Pothuri B; Auranen A; Chase DM; Lorusso D; Anderson C; Abadie-Lacourtoisie S; Cloven N; Braicu EI; Amit A; Redondo A; Shah R; Kebede N; Hawkes C; Gupta D; Woodward T; O'Malley DM; González-Martín A
Ther Adv Med Oncol; 2022; 14():17588359221126149. PubMed ID: 36172173
[TBL] [Abstract][Full Text] [Related]
3. Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer.
González-Martín A; Pothuri B; Vergote I; Graybill W; Lorusso D; McCormick CC; Freyer G; Backes F; Heitz F; Redondo A; Moore RG; Vulsteke C; O'Cearbhaill RE; Malinowska IA; Shtessel L; Compton N; Mirza MR; Monk BJ
Eur J Cancer; 2023 Aug; 189():112908. PubMed ID: 37263896
[TBL] [Abstract][Full Text] [Related]
4. Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial.
Pothuri B; Han S; Chase DM; Heitz F; Burger RA; Gaba L; Van Le L; Guerra E; Bender D; Korach J; Cloven N; Churruca C; Follana P; DiSilvestro P; Baurain JF; Jardon K; Pisano C; Peen U; Mäenpää J; Gupta D; Bacqué E; Li Y; Compton N; Antonova J; Monk BJ; González-Martín A
Gynecol Oncol; 2024 May; 184():168-177. PubMed ID: 38325276
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
Valabrega G; Pothuri B; Oaknin A; Graybill WS; Sánchez AB; McCormick C; Baurain JF; Tinker AV; Denys H; O'Cearbhaill RE; Hietanen S; Moore RG; Knudsen AØ; de La Motte Rouge T; Heitz F; Levy T; York W; Gupta D; Monk BJ; González-Martín A
Gynecol Oncol; 2024 Jun; 187():128-138. PubMed ID: 38833992
[TBL] [Abstract][Full Text] [Related]
6. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
González-Martín A; Pothuri B; Vergote I; DePont Christensen R; Graybill W; Mirza MR; McCormick C; Lorusso D; Hoskins P; Freyer G; Baumann K; Jardon K; Redondo A; Moore RG; Vulsteke C; O'Cearbhaill RE; Lund B; Backes F; Barretina-Ginesta P; Haggerty AF; Rubio-Pérez MJ; Shahin MS; Mangili G; Bradley WH; Bruchim I; Sun K; Malinowska IA; Li Y; Gupta D; Monk BJ;
N Engl J Med; 2019 Dec; 381(25):2391-2402. PubMed ID: 31562799
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study.
O'Cearbhaill RE; Pérez-Fidalgo JA; Monk BJ; Tusquets I; McCormick C; Fuentes J; Moore RG; Vulsteke C; Shahin MS; Forget F; Bradley WH; Hietanen S; O'Malley DM; Dørum A; Slomovitz BM; Baumann K; Selle F; Calvert PM; Artioli G; Levy T; Kumar A; Malinowska IA; Li Y; Gupta D; González-Martín A
Gynecol Oncol; 2022 Jul; 166(1):36-43. PubMed ID: 35550709
[TBL] [Abstract][Full Text] [Related]
8. Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
Mirza MR; González-Martín A; Graybill WS; O'Malley DM; Gaba L; Stephanie Yap OW; Guerra EM; Rose PG; Baurain JF; Ghamande SA; Denys H; Prendergast E; Pisano C; Follana P; Baumann K; Calvert PM; Korach J; Li Y; Malinowska IA; Gupta D; Monk BJ
Cancer; 2023 Jun; 129(12):1846-1855. PubMed ID: 37060236
[TBL] [Abstract][Full Text] [Related]
9. Optimizing disease progression assessment using blinded central independent review and comparing it with investigator assessment in the PRIMA/ENGOT-ov26/GOG-3012 trial: challenges and solutions.
Herzog TJ; Wahab SA; Mirza MR; Pothuri B; Vergote I; Graybill WS; Malinowska IA; York W; Hurteau JA; Gupta D; González-Martin A; Monk BJ
Int J Gynecol Cancer; 2023 Nov; 33(11):1733-1742. PubMed ID: 37931976
[TBL] [Abstract][Full Text] [Related]
10. AGO-OVAR 28/ENGOT-ov57. Niraparib alone versus niraparib in combination with bevacizumab in patients with carboplatin-taxane-based chemotherapy in advanced ovarian cancer: a multicenter randomized phase III trial.
Heitz F; Marth C; Henry S; Reuss A; Cibula D; Gaba Garcia L; Colombo N; Schmalfeld B; de Gregorio N; Wimberger P; Hasenburg A; Sehouli J; Gropp-Meier M; Schouten PC; Hahnen E; Hauke J; Polleis S; Harter P
Int J Gynecol Cancer; 2023 Dec; 33(12):1966-1969. PubMed ID: 37935524
[TBL] [Abstract][Full Text] [Related]
11. Homologous Recombination Deficiency Testing to Inform Patient Decisions About Niraparib Maintenance Therapy for High-Grade Serous or Endometrioid Epithelial Ovarian Cancer: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2023; 23(5):1-188. PubMed ID: 37637244
[TBL] [Abstract][Full Text] [Related]
12. Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: study protocol for cohort C of the open-label, phase 2, randomized controlled multicenter OPAL trial.
Belotte J; Felicetti B; Baines AJ; YoussefAgha A; Rojas-Espaillat L; Ortiz AG; Provencher D; Vázquez RM; Cortijo LG; Zeng X
Trials; 2024 May; 25(1):301. PubMed ID: 38702828
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.
Mirza MR; Benigno B; Dørum A; Mahner S; Bessette P; Barceló IB; Berton-Rigaud D; Ledermann JA; Rimel BJ; Herrstedt J; Lau S; du Bois A; Herráez AC; Kalbacher E; Buscema J; Lorusso D; Vergote I; Levy T; Wang P; de Jong FA; Gupta D; Matulonis UA
Gynecol Oncol; 2020 Nov; 159(2):442-448. PubMed ID: 32981695
[TBL] [Abstract][Full Text] [Related]
14. NIRVANA-1: maintenance therapy with niraparib versus niraparib-bevacizumab in patients with advanced ovarian cancer.
Sghaier S; Corbaux P; Ray-Coquard I; Lim MC; Hasegawa K; Nieuwenhuysen EV; Gonzalez A; Raspagliesi F; Freyer G
Future Oncol; 2023 Aug; 19(25):1715-1727. PubMed ID: 37650734
[TBL] [Abstract][Full Text] [Related]
15. A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial.
Gonzalez Martin A; Sanchez Lorenzo L; Colombo N; dePont Christensen R; Heitz F; Meirovitz M; Selle F; van Gorp T; Alvarez N; Sanchez J; Marqués C
Int J Gynecol Cancer; 2021 Apr; 31(4):617-622. PubMed ID: 33318079
[TBL] [Abstract][Full Text] [Related]
16. Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial.
Li N; Zhu J; Yin R; Wang J; Pan L; Kong B; Zheng H; Liu J; Wu X; Wang L; Huang Y; Wang K; Zou D; Zhao H; Wang C; Lu W; Lin A; Lou G; Li G; Qu P; Yang H; Zhang Y; Cai H; Pan Y; Hao M; Liu Z; Cui H; Yang Y; Yao S; Zhen X; Hang W; Hou J; Wang J; Wu L
JAMA Oncol; 2023 Sep; 9(9):1230-1237. PubMed ID: 37440217
[TBL] [Abstract][Full Text] [Related]
17. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial.
Oza AM; Matulonis UA; Malander S; Hudgens S; Sehouli J; Del Campo JM; Berton-Rigaud D; Banerjee S; Scambia G; Berek JS; Lund B; Tinker AV; Hilpert F; Vázquez IP; D'Hondt V; Benigno B; Provencher D; Buscema J; Agarwal S; Mirza MR
Lancet Oncol; 2018 Aug; 19(8):1117-1125. PubMed ID: 30026000
[TBL] [Abstract][Full Text] [Related]
18. [Real-world clinical data analysis of PARPi as first-line maintenance therapy in newly diagnosed epithelial ovarian cancer patients].
Wang DF; Zhang J; Zhang C; Yu J; Shi Y; Xu SQ; Fan Y; Zhou FZ; Song SQ; Liu H; Zhang GN
Zhonghua Fu Chan Ke Za Zhi; 2022 Sep; 57(9):641-652. PubMed ID: 36177575
[No Abstract] [Full Text] [Related]
19. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
Mirza MR; Åvall Lundqvist E; Birrer MJ; dePont Christensen R; Nyvang GB; Malander S; Anttila M; Werner TL; Lund B; Lindahl G; Hietanen S; Peen U; Dimoula M; Roed H; Ør Knudsen A; Staff S; Krog Vistisen A; Bjørge L; Mäenpää JU;
Lancet Oncol; 2019 Oct; 20(10):1409-1419. PubMed ID: 31474354
[TBL] [Abstract][Full Text] [Related]
20. Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab
Hettle R; McCrea C; Lee CK; Davidson R
Ther Adv Med Oncol; 2021; 13():17588359211049639. PubMed ID: 34616492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
